Insulet Corp
PODD289.620USD
-3.260-1.11%
Handelsschluss 12/19, 16:00（ET）Kurse um 15 Minuten verzögert
20.37BMarktkapitalisierung
82.66KGV TTM
mehr Informationen über Insulet Corp Unternehmen
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
Insulet Corp Informationen
BörsenkürzelPODD
Name des UnternehmensInsulet Corp
IPO-datumMay 15, 2007
CEOMcevoy (Ashley)
Anzahl der mitarbeiter3900
WertpapierartOrdinary Share
GeschäftsjahresendeMay 15
Addresse100 Nagog Park
StadtACTON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl01720-3440
Telefon19786007000
Websitehttps://www.omnipod.com
BörsenkürzelPODD
IPO-datumMay 15, 2007
CEOMcevoy (Ashley)
Führungskräfte von Insulet Corp
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Director
Independent Director
27.70K
+2.89%
Mr. Michael R. Minogue
Mr. Michael R. Minogue
Independent Director
Independent Director
14.85K
-8.50%
Mr. Eric Benjamin
Mr. Eric Benjamin
Chief Operating Officer
Chief Operating Officer
10.47K
-28.94%
Ms. Ashley Mcevoy
Ms. Ashley Mcevoy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
9.54K
+238500.00%
Ms. Elizabeth H. (Bess) Weatherman
Ms. Elizabeth H. (Bess) Weatherman
Independent Director
Independent Director
5.24K
+17.43%
Ms. Lauren Budden
Ms. Lauren Budden
Chief Accounting Officer, Group Vice President, Corporate Controller
Chief Accounting Officer, Group Vice President, Corporate Controller
5.22K
+17.01%
Mr. Timothy C. (Tim) Stonesifer
Mr. Timothy C. (Tim) Stonesifer
Independent Director
Independent Director
3.85K
+33.25%
Ms. Laetitia Cousin
Ms. Laetitia Cousin
Senior Vice President - Regulatory Affairs, Quality Assurance and Compliance
Senior Vice President - Regulatory Affairs, Quality Assurance and Compliance
3.58K
--
Mr. Prem Singh
Mr. Prem Singh
Senior Vice President - Global Operations
Senior Vice President - Global Operations
3.56K
-16.16%
Dr. Luciana Borio, M.D.
Dr. Luciana Borio, M.D.
Independent Director
Independent Director
3.09K
-13.48%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Director
Independent Director
27.70K
+2.89%
Mr. Michael R. Minogue
Mr. Michael R. Minogue
Independent Director
Independent Director
14.85K
-8.50%
Mr. Eric Benjamin
Mr. Eric Benjamin
Chief Operating Officer
Chief Operating Officer
10.47K
-28.94%
Ms. Ashley Mcevoy
Ms. Ashley Mcevoy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
9.54K
+238500.00%
Ms. Elizabeth H. (Bess) Weatherman
Ms. Elizabeth H. (Bess) Weatherman
Independent Director
Independent Director
5.24K
+17.43%
Ms. Lauren Budden
Ms. Lauren Budden
Chief Accounting Officer, Group Vice President, Corporate Controller
Chief Accounting Officer, Group Vice President, Corporate Controller
5.22K
+17.01%
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
U.S.Omnipod
453.20M
69.82%
International Omnipod
185.80M
28.62%
Drug Delivery
10.20M
1.57%
Nach RegionUSD
Name
Umsatz
Anteil
United States
463.30M
71.38%
All Other
185.80M
28.62%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
U.S.Omnipod
453.20M
69.82%
International Omnipod
185.80M
28.62%
Drug Delivery
10.20M
1.57%
Aktionärsstatistik
Aktualisiert: Sun, Nov 16
Aktualisiert: Sun, Nov 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
12.46%
Fidelity Management & Research Company LLC
9.83%
Capital Research Global Investors
6.47%
BlackRock Institutional Trust Company, N.A.
6.29%
State Street Investment Management (US)
4.39%
Andere
60.56%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
12.46%
Fidelity Management & Research Company LLC
9.83%
Capital Research Global Investors
6.47%
BlackRock Institutional Trust Company, N.A.
6.29%
State Street Investment Management (US)
4.39%
Andere
60.56%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
64.92%
Investment Advisor/Hedge Fund
23.48%
Hedge Fund
4.88%
Pension Fund
2.61%
Research Firm
2.52%
Sovereign Wealth Fund
1.57%
Bank and Trust
1.22%
Individual Investor
0.30%
Family Office
0.05%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
1546
72.07M
102.39%
-3.66M
2025Q2
1541
72.80M
103.47%
-3.81M
2025Q1
1569
72.82M
103.50%
-3.52M
2024Q4
1508
72.57M
103.34%
-4.94M
2024Q3
1436
73.14M
104.31%
-3.15M
2024Q2
1408
72.17M
103.04%
-3.02M
2024Q1
1350
71.60M
102.26%
-3.12M
2023Q4
1320
72.91M
104.42%
-1.52M
2023Q3
1254
72.05M
103.19%
-4.06M
2023Q2
1223
73.42M
105.35%
-3.44M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
8.68M
12.33%
+38.89K
+0.45%
Jun 30, 2025
Fidelity Management & Research Company LLC
6.86M
9.74%
-271.19K
-3.80%
Jun 30, 2025
Capital Research Global Investors
4.74M
6.73%
-1.34M
-22.06%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.35M
6.18%
-13.40K
-0.31%
Jun 30, 2025
State Street Investment Management (US)
3.06M
4.34%
+32.74K
+1.08%
Jun 30, 2025
Baillie Gifford & Co.
2.14M
3.03%
-115.69K
-5.14%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.93M
2.74%
+58.31K
+3.12%
Jun 30, 2025
ClearBridge Investments, LLC
1.54M
2.18%
+56.63K
+3.83%
Jun 30, 2025
American Century Investment Management, Inc.
1.31M
1.86%
+157.07K
+13.63%
Jun 30, 2025
Fidelity International
1.13M
1.61%
-155.38K
-12.09%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Langar Global HealthTech ETF
7.26%
Innovator IBD Breakout Opportunities ETF
4.88%
Global X HealthTech ETF
4.76%
Goldman Sachs Future Health Care Equity ETF
4.2%
First Trust Nasdaq Lux Digi Health Solutions ETF
3.7%
iShares Health Innovation Active ETF
3%
Congress SMid Growth ETF
2.82%
iShares U.S. Medical Devices ETF
2.62%
FT Raymond James Multicap Growth Equity ETF
2.3%
Acruence Active Hedge US Equity ETF
2.27%
Mehr Anzeigen
Langar Global HealthTech ETF
Anteil7.26%
Innovator IBD Breakout Opportunities ETF
Anteil4.88%
Global X HealthTech ETF
Anteil4.76%
Goldman Sachs Future Health Care Equity ETF
Anteil4.2%
First Trust Nasdaq Lux Digi Health Solutions ETF
Anteil3.7%
iShares Health Innovation Active ETF
Anteil3%
Congress SMid Growth ETF
Anteil2.82%
iShares U.S. Medical Devices ETF
Anteil2.62%
FT Raymond James Multicap Growth Equity ETF
Anteil2.3%
Acruence Active Hedge US Equity ETF
Anteil2.27%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Insulet Corp?
Die fünf größten Anteilseigner von Insulet Corp sind:
The Vanguard Group, Inc. hält 8.68M Aktien, was 12.33% der Gesamtaktien entspricht.
Fidelity Management & Research Company LLC hält 6.86M Aktien, was 9.74% der Gesamtaktien entspricht.
Capital Research Global Investors hält 4.74M Aktien, was 6.73% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 4.35M Aktien, was 6.18% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 3.06M Aktien, was 4.34% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 8.68M Aktien, was 12.33% der Gesamtaktien entspricht.
Fidelity Management & Research Company LLC hält 6.86M Aktien, was 9.74% der Gesamtaktien entspricht.
Capital Research Global Investors hält 4.74M Aktien, was 6.73% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 4.35M Aktien, was 6.18% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 3.06M Aktien, was 4.34% der Gesamtaktien entspricht.
Was sind die drei wichtigsten Anteilseigner-Typen von Insulet Corp?
Die drei wichtigsten Anteilseigner-Typen von Insulet Corp sind:
The Vanguard Group, Inc.
Fidelity Management & Research Company LLC
Capital Research Global Investors
The Vanguard Group, Inc.
Fidelity Management & Research Company LLC
Capital Research Global Investors
Wie viele Institutionen halten Anteile an Insulet Corp (PODD)?
Mit Stand vom 2025Q3 halten 1546 Institutionen Anteile an Insulet Corp, mit einem Gesamtmarktwert von etwa 72.07M, was 102.39% der Gesamtanteile entspricht. Im Vergleich zum 2025Q2 ist der institutionelle Aktienbesitz um -1.08% gestiegen.
Was ist die größte Einnahmequelle von Insulet Corp?
Am FY2025Q2 erzielte das Geschäft mit U.S.Omnipod für Insulet Corp den höchsten Umsatz in Höhe von 453.20M, was 69.82% des Gesamtumsatzes entspricht.
